AbbVie Just Dropped $10.9 Billion on a Company That Didn't Exist Four Years Ago
AbbVie is paying $10.9 billion in cash for Apogee Therapeutics, a company that was founded just four years ago. The prize: an eczema drug that could challenge Dupixent with dramatically less frequent dosing. Wall Street says the price is steep but justified.
From Zero to $10.9 Billion in Four Years
In 2022, two healthcare investment firms spun a company out of a discovery shop called Paragon Therapeutics. They gave it $169 million and a simple thesis: build better antibodies for inflammatory diseases. The company was called Apogee Therapeutics.
Four years later, AbbVie is buying it for $10.9 billion in cash.
That's not a typo. A company that IPO'd at $17 per share in July 2023 just got acquired for $135.11 per share. If you bought Apogee stock on its first day of trading, you made roughly 8x your money in under three years. Venture investors Fairmount Funds and Venrock Healthcare Capital Partners, who co-founded the company, are having a very good week.
But this deal isn't really about Apogee's origin story. It's about what AbbVie is willing to pay to stay relevant in immunology, and what that says about the future of the eczema drug market.
The Drug That Caught AbbVie's Eye
Apogee's crown jewel is zumilokibart, a biologic designed to treat moderate-to-severe atopic dermatitis (the clinical name for serious eczema). It works by blocking IL-13, one of the key proteins that drives the inflammation behind eczema flares.
Plenty of drugs target this pathway. What makes zumilokibart different is how rarely patients need it. In Phase 2 maintenance data, 75% of patients dosed once every three months kept their skin clear after a full year. Among those dosed just twice a year, that number was actually higher: 85%.
Compare that to Dupixent, the current king of eczema biologics, which requires an injection every two weeks. That's 26 shots per year versus two or four. If you've ever tried to maintain any health regimen (hello, flossing), you understand why dosing frequency matters.
The efficacy numbers are competitive too. In the Phase 2 trial, 65.9% of zumilokibart patients hit the key skin-clearance benchmark (called EASI-75) at 16 weeks, versus 23.4% on placebo. Apogee has claimed that's the highest EASI-75 rate for any biologic in a global study, though no head-to-head trials exist to prove it definitively.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
AbbVie's Post-Humira Anxiety
To understand why AbbVie wrote a check this big, you need to understand the company's existential challenge.
For nearly two decades, Humira was AbbVie's everything. The anti-inflammatory blockbuster generated over $20 billion in annual sales at its peak, making it the best-selling drug in pharmaceutical history. Then biosimilars arrived, and that revenue started evaporating.
AbbVie's response was to bet heavily on two successor drugs: Skyrizi (for psoriasis and IBD) and Rinvoq (a JAK inhibitor for multiple inflammatory diseases). The company expects those two products to generate more than $27 billion combined by 2027. That's an impressive replacement strategy.
But Wall Street always wants to know what comes next. Skyrizi and Rinvoq can't grow forever. AbbVie needs a pipeline that extends its immunology dominance into the 2030s. And in a world where high-quality immunology assets are scarce, that means paying up.
Enter zumilokibart.
The Eczema Market Is Enormous (and Getting Bigger)
Atopic dermatitis isn't a niche condition. The global market for AD drugs sits in the mid-to-high teens of billions of dollars and is growing at roughly 10-11% annually.
Right now, one product dominates that market: Dupixent, made by Regeneron and Sanofi. In 2024, Dupixent pulled in roughly $14 billion in total sales across all its indications, with an estimated $7 billion or more coming from eczema alone. It's approved for patients as young as six months old, locked into payer formularies, and prescribed across asthma, nasal polyps, and several other conditions. That multi-indication footprint gives it enormous contracting leverage with insurers.
Think of Dupixent as the iPhone of eczema drugs: it was first to market, it works well, and the entire ecosystem is built around it. Displacing it isn't just about having better clinical data. You need a reason compelling enough to make doctors, patients, and insurers switch.
"Inject yourself six times a year instead of 26" is a pretty compelling reason.
What Wall Street Thinks of the Price Tag
At $135.11 per share, AbbVie is paying a 49% premium over Apogee's last closing price of $90.38. Net of Apogee's cash reserves, the deal values the operating business at roughly $10.1 billion.
That's a lot of money for a company whose lead drug hasn't started Phase 3 yet. AbbVie itself acknowledged the deal won't become accretive until 2032. Six years of waiting is a long time in pharma.
But analysts are largely shrugging. Citi called the premium "not excessive," citing the scarcity of quality immunology assets and Apogee's strong Phase 2 data. J.P. Morgan described it as a "strong strategic fit" that leverages AbbVie's commercial infrastructure. RBC Capital Markets noted that Apogee had "long been considered an acquisition candidate" and called AbbVie an "ideal acquirer."
The consensus view: the price is full but justifiable, given what's at stake.
Guggenheim Securities had previously doubled their peak sales forecast for zumilokibart to $5.2 billion after seeing the Phase 2 data. If that number pans out, paying $10 billion for it looks reasonable. If zumilokibart stumbles in Phase 3, it looks like an expensive mistake.
The Competition Isn't Standing Still
AbbVie isn't the only company eyeing this market. The eczema landscape is getting crowded, and each competitor brings a different angle.
Eli Lilly's lebrikizumab (Ebglyss) is another IL-13 antibody, already approved in Europe for adults with eczema. In March 2026, Lilly reported positive pediatric trial results, directly targeting one of Dupixent's biggest advantages: its broad age coverage.
AbbVie's own Rinvoq competes here too, as an oral JAK inhibitor approved for AD since 2022. JAK inhibitors offer fast itch relief and the convenience of a pill, but they carry black-box safety warnings (blood clots, cancer risk, serious infections) that make doctors cautious about long-term use.
Then there are the emerging players. Galderma's nemolizumab (Nemluvio) targets a completely different pathway (IL-31, focused on itch) and has already received FDA approval and launched in multiple major markets. Sanofi's amlitelimab, which blocks OX40L, showed strong Phase 3 results with every-12-week dosing.
The pattern is clear: the next generation of eczema drugs is competing on convenience and dosing frequency, not just efficacy. Zumilokibart's every-three-to-six-month dosing would be best-in-class if confirmed in Phase 3. That's AbbVie's bet.
Three Phase 3 Trials, One Big Question
Apogee had already mapped out its Phase 3 program before AbbVie came knocking. The plan calls for three trials, collectively called ADventure, set to begin in the second half of 2026:
ADventure 1 and 2: monotherapy studies (the classic "drug versus placebo" setup)
ADventure TCS: zumilokibart combined with topical corticosteroids (steroid creams)
Each trial will enroll roughly 400 patients with moderate-to-severe eczema, running a 16-week treatment period followed by monitoring through Week 52. The primary goals: proving that zumilokibart clears skin (EASI-75) and achieves near-normal skin appearance (IGA 0/1) at 16 weeks.
If everything goes well, Apogee's internal timeline pointed to a potential launch around 2029. Under AbbVie's ownership, with deeper pockets and a massive commercial team already selling immunology drugs, that timeline could hold or even accelerate.
The Bigger Picture
This deal tells you three things about where biotech is heading in 2026.
First, immunology assets command insane premiums. When Citi says the price "doesn't seem excessive" for a Phase 2 company, you know supply and demand are wildly out of balance. Every big pharma company wants to own the next generation of anti-inflammatory drugs, and there aren't enough good ones to go around.
Second, dosing convenience is the new battleground. The eczema drugs of 2024 mostly work well enough. What patients and doctors want now is less hassle. Every-two-week injections were revolutionary when Dupixent launched. But quarterly or twice-yearly dosing? That changes the entire treatment experience. The company that delivers both efficacy and convenience wins.
Third, AbbVie is playing offense, not defense. This isn't a desperate move from a company watching its revenue disappear. AbbVie has Skyrizi and Rinvoq firing on all cylinders. Buying Apogee is about extending the dynasty, not saving it. As Citi noted, AbbVie "may still need another deal" to fully build out its post-Humira growth story. This is chapter one, not the whole book.
The deal is expected to close in Q3 2026, pending shareholder approval and regulatory clearance. Both boards have unanimously approved it, and key shareholders (including Apogee's founding investors) have already signed voting agreements in support.
For a company that literally didn't exist in January 2022, that's not a bad ending. Or beginning, depending on how you look at it.
Deals & M&A
5 min read
The $2.5 Billion Bet That AI Can Crack the Brain's Immune System
SK Biopharmaceuticals just signed one of the largest AI drug discovery deals ever with Insilico Medicine, worth up to $2.5 billion. The catch? Only $18 million is guaranteed upfront, and the rest hinges on cracking one of medicine's hardest puzzles: neuroimmune disease.
